Nkarta (NKTX) Competitors $2.08 -0.07 (-3.02%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NKTX vs. PHAR, CGEM, SEPN, MAZE, VALN, STOK, CMPX, XERS, MGTX, and HUMAShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Pharming Group (PHAR), Cullinan Therapeutics (CGEM), Septerna (SEPN), Maze Therapeutics (MAZE), Valneva (VALN), Stoke Therapeutics (STOK), Compass Therapeutics (CMPX), Xeris Biopharma (XERS), MeiraGTx (MGTX), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Pharming Group Cullinan Therapeutics Septerna Maze Therapeutics Valneva Stoke Therapeutics Compass Therapeutics Xeris Biopharma MeiraGTx Humacyte Pharming Group (NASDAQ:PHAR) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability. Does the media refer more to PHAR or NKTX? In the previous week, Nkarta had 8 more articles in the media than Pharming Group. MarketBeat recorded 8 mentions for Nkarta and 0 mentions for Pharming Group. Nkarta's average media sentiment score of 0.98 beat Pharming Group's score of 0.00 indicating that Nkarta is being referred to more favorably in the news media. Company Overall Sentiment Pharming Group Neutral Nkarta Positive Does the MarketBeat Community prefer PHAR or NKTX? Nkarta received 40 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 76.92% of users gave Nkarta an outperform vote while only 64.52% of users gave Pharming Group an outperform vote. CompanyUnderperformOutperformPharming GroupOutperform Votes2064.52% Underperform Votes1135.48% NkartaOutperform Votes6076.92% Underperform Votes1823.08% Which has more volatility and risk, PHAR or NKTX? Pharming Group has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Which has stronger valuation & earnings, PHAR or NKTX? Pharming Group has higher revenue and earnings than Nkarta. Pharming Group is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$245.32M2.54-$10.55M-$0.26-35.17NkartaN/AN/A-$117.50M-$1.88-1.11 Do insiders and institutionals believe in PHAR or NKTX? 0.0% of Pharming Group shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 8.7% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is PHAR or NKTX more profitable? Nkarta has a net margin of 0.00% compared to Pharming Group's net margin of -6.09%. Pharming Group's return on equity of -7.65% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-6.09% -7.65% -3.82% Nkarta N/A -27.13%-21.67% Do analysts prefer PHAR or NKTX? Pharming Group presently has a consensus price target of $27.00, suggesting a potential upside of 195.24%. Nkarta has a consensus price target of $15.00, suggesting a potential upside of 619.42%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Pharming Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Nkarta 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 SummaryNkarta beats Pharming Group on 13 of the 18 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.14M$7.05B$5.81B$9.13BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-1.115.9925.9319.18Price / SalesN/A324.61463.3381.20Price / CashN/A67.8344.0437.47Price / Book0.386.827.714.77Net Income-$117.50M$138.11M$3.18B$245.80M7 Day Performance-5.66%-0.60%-0.52%-0.80%1 Month Performance-14.55%-0.08%1.71%-0.44%1 Year Performance-78.12%-2.10%18.52%16.44% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.6716 of 5 stars$2.09-3.0%$15.00+619.4%-79.2%$147.14MN/A-1.11140Positive NewsPHARPharming Group2.316 of 5 stars$8.66-1.4%$27.00+211.8%-18.7%$589.14M$245.32M-33.31280CGEMCullinan Therapeutics2.3941 of 5 stars$10.12-0.9%$32.50+221.1%-47.4%$588.41MN/A-3.5630SEPNSepternaN/A$13.04-0.4%$43.67+235.0%N/A$578.98MN/A0.00N/AAnalyst DowngradeAnalyst RevisionNews CoverageGap UpMAZEMaze TherapeuticsN/A$12.90-3.6%N/AN/A$564.76MN/A0.00121VALNValneva2.2661 of 5 stars$6.88+6.3%$17.50+154.4%+9.6%$559.07M$165.52M-52.92700Analyst ForecastAnalyst RevisionGap UpSTOKStoke Therapeutics3.763 of 5 stars$10.30-9.2%$21.29+106.6%+62.5%$547.82M$8.78M-4.92100Analyst ForecastAnalyst RevisionNews CoverageCMPXCompass Therapeutics3.3795 of 5 stars$3.89+11.2%$11.80+203.2%+67.3%$535.91MN/A-10.5320Analyst ForecastGap UpXERSXeris Biopharma3.7967 of 5 stars$3.56+0.1%$5.15+44.9%+25.6%$529.98M$163.91M-7.90290News CoverageMGTXMeiraGTx3.943 of 5 stars$6.68-1.9%$23.50+251.8%+15.8%$521.26M$14.02M-5.51300HUMAHumacyte3.1875 of 5 stars$4.13-0.6%$13.71+232.5%-22.5%$519.17M$1.57M-3.08150Short Interest ↓Positive News Related Companies and Tools Related Companies Pharming Group Competitors Cullinan Therapeutics Competitors Septerna Competitors Maze Therapeutics Competitors Valneva Competitors Stoke Therapeutics Competitors Compass Therapeutics Competitors Xeris Biopharma Competitors MeiraGTx Competitors Humacyte Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NKTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTX Stock Alerts